Mannheimia haemolytica growth and leukotoxin production for vaccine manufacturing – A bioprocess review
PDF

Keywords

bovine respiratory disease
cell growth
commensal flora of cattle
enzootic calf pneumonia
facultatively anaerobic
gram-negative
leukotoxin production
mastitis in sheep
operational parameters
Pasteurella haemolytica
rod-shaped bacteria

How to Cite

1.
Oppermann T, Busse N, Czermak P. Mannheimia haemolytica growth and leukotoxin production for vaccine manufacturing – A bioprocess review. Electron. J. Biotechnol. [Internet]. 2017 Sep. 6 [cited 2024 Nov. 4];28(1). Available from: https://www.ejbiotechnology.info/index.php/ejbiotechnology/article/view/2017.06.001

Abstract

Mannheimia haemolytica leukotoxin (LKT) is a known cause of bovine respiratory disease (BRD) which results in severe economic losses in the cattle industry (up to USD 1 billion per year in the USA). Vaccines based on LKT offer the most promising measure to contain BRD outbreaks and are already commercially available. However, insufficient LKT yields, predominantly reflecting a lack of knowledge about the LKT expression process, remain a significant engineering problem and further bioprocess optimization is required to increase process efficiency. Most previous investigations have focused on LKT activity and cell growth, but neither of these parameters defines reliable criteria for the improvement of LKT yields. In this article, we review the most important process conditions and operational parameters (temperature, pH, substrate concentration, dissolved oxygen level, medium composition and the presence of metabolites) from a bioprocess engineering perspective, in order to maximize LKT yields.

PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.